Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Antitumor Activity of MSC-1 in Patients With Advanced Solid Tumors

NCT03490669 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT03490669
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03490669 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Antitumor Activity of MSC-1 in Patients With Advanced Solid Tumors
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Completed
Start date
May 21, 2018
Completion date
September 23, 2019
Enrollment
41 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors, non small cell lung cancer, ovarian cancer, pancreatic cancer